SCHEMBL7164683

SCHEMBL7164683

CCOC(=O)c1cnc2c(CC)cc(C#N)cc2c1NCc1cccc(Cl)c1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 7/20 0.75
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 8/20 0.47
LMNA P02545 3/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
THRB P10828 1/20 0.46
VNN1 O95497 1/20 0.45
ADORA1 P30542 1/20 0.45
MEN1 O00255 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
POLB P06746 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170874 0.91 PDE5A (0.74) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7167673 0.90 PDE5A (0.73) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7167103 0.89 PDE5A (0.84) PDE5AKDM4EMAPTTHRBPOLB
SCHEMBL7167896 0.87 PDE5A (0.67) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7163184 0.87 PDE5A (0.73) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7167198 0.87 PDE5A (0.66) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7160498 0.87 PDE5A (0.75) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL7168952 0.86 PDE5A (0.70) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL4993052 0.86 PDE5A (1.00) PDE5A
SCHEMBL7165631 0.85 PDE5A (0.73) PDE5AALDH1A1KDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase BI YINGZHI (US) 2003-12-04 US claimed
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase BRISTOL-MYERS SQUIBB COMPANY 2002-11-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225128-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE3A, PDE2A PDE5A 1/4885ALDH1A1 301/4885KDM4E 2418/4885
US-20020177587-A1 Quinoline inhibitors of cGMP phosphodiesterase PDE5A, PDE2A, PDE3A PDE5A 1/4885ALDH1A1 709/4885KDM4E 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.